Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discovery of Sirolimus Sensitive Biomarkers in Blood
NCT03304678Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Dec 2017
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in lymphangioleiomyomatosis (LAM), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Number of Sirolimus-Sensitive Plasma Protein Biomarkers in Lymphangioleiomyomatosis (LAM) Participants at Month 9. Started Dec 2017; status: completed.
02
Drugs
sirolimus
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT03304678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03304678.